









Markets
/
Stocks
/
nasdaq-srpt
/

Sarepta Therapeutics Inc

SRPT

24.450USD

+0.440+1.83%

Close 11/03, 16:00（ET）Quotes delayed by 15 min

2.39BMarket Cap

LossP/E TTM



Sarepta Therapeutics Inc

24.450

+0.440+1.83%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Sarepta Therapeutics Inc

Currency: USD Updated: 2025-11-03

Key Insights

The company's fundamentals are relatively stable. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Hold. The company is performing well in the stock market, with strong fundamentals and technicals supporting the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Sarepta Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

79 / 159

Overall Ranking

211 / 4617

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 29 analysts

Hold

Current Rating

32.399

Target Price

+34.94%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Sarepta Therapeutics Inc Highlights

StrengthsRisks

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 103.85% year-on-year.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD .

Undervalued

The company’s latest PE is -45.04, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 84.37M shares, decreasing 19.56% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 63.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 2.36.

Financial Health

Currency: USD Updated: 2025-11-03

The company's current financial score is 8.43, which is higher than the Pharmaceuticals industry's average of 7.76. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 611.09M, representing a year-over-year increase of 68.38%, while its net profit experienced a year-over-year increase of 2947.86%.

Score

Industry at a Glance

Previous score

8.43

Change



Financials

5.67

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.75

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.71

Key Metrics

Free cash flow

No Data

Sarepta Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-03

The company’s current valuation score is 7.20, which is lower than the Pharmaceuticals industry's average of 7.21. Its current P/E ratio is -45.04, which is -920.43% below the recent high of 369.56 and 0.00% above the recent low of -45.04.

Score

Industry at a Glance

Previous score

7.20

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 79/159

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-03

The company’s current earnings forecast score is 6.48, which is lower than the Pharmaceuticals industry's average of 7.77. The average price target for Sarepta Therapeutics Inc is 18.00, with a high of 185.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

6.41

Change

0.07

Support & Resistance

No Data

Analyst Rating

Based on 29 analysts

Hold

Current Rating

32.399

Target Price

+34.94%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

169

Total

Median

Average

Company name

Ratings

Analysts

Sarepta Therapeutics Inc

SRPT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-03

The company’s current price momentum score is 6.26, which is lower than the Pharmaceuticals industry's average of 7.00. Sideways: Currently, the stock price is trading between the resistance level at 26.21 and the support level at 21.80, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

5.71

Change

0.55

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(1)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

0.021

Buy

RSI(14)

62.889

Neutral

STOCH(KDJ)(9,3,3)

86.957

Overbought

ATR(14)

1.269

High Vlolatility

CCI(14)

100.457

Buy

Williams %R

3.067

Overbought

TRIX(12,20)

0.677

Sell

StochRSI(14)

84.353

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

23.876

Buy

MA10

23.340

Buy

MA20

22.982

Buy

MA50

20.355

Buy

MA100

19.517

Buy

MA200

47.109

Sell

Institutional Confidence

Currency: USD Updated: 2025-11-03

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.74. The latest institutional shareholding proportion is 80.60%, representing a quarter-over-quarter decrease of 17.88%. The largest institutional shareholder is The Vanguard, holding a total of 10.64M shares, representing 10.17% of shares outstanding, with 8.66% increase in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

10.64M

+16.51%

BlackRock Institutional Trust Company, N.A.

9.84M

+10.53%

D. E. Shaw & Co., L.P.

5.06M

+12.98%

State Street Investment Management (US)

4.70M

+15.40%

Two Sigma Investments, LP

4.15M

+397.77%

Barry (Richard J)

3.21M

+1.02%

Wellington Management Company, LLP

2.53M

-4.39%

Geode Capital Management, L.L.C.

1.88M

+3.02%

Erste Asset Management GmbH

1.62M

+52.81%

Qube Research & Technologies Ltd

1.60M

+4909.63%

Risk Assessment

Currency: USD Updated: 2025-11-03

The company’s current risk assessment score is 2.67, which is lower than the Pharmaceuticals industry's average of 5.15. The company's beta value is 0.52. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.